BioPharma Dive November 14, 2025
The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of recent buyout deals involving portfolio companies like Merus and Vicebio.
Medicxi, a European life sciences venture capital firm, said Friday it raised 500 million euros, or about $579 million, for its sixth investment fund.
The firm will use the new bankroll to continue “asset-centric” investing, or building new companies around one or a few experimental “products” rather than broad drugmaking “platforms.” It’ll also support other, existing biotechs that align with its focus, regardless of their stage of development.
“Especially in times where generally in the market, capital is constrained, it helps us really focus on the stories that...
Today's Sponsors
Today's Sponsor